Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
Sign Up to like & getrecommendations! Published in 2020 at "The Lancet"
DOI: 10.1016/s0140-6736(20)30609-7
Abstract: BACKGROUND Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life. There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for… read more here.
Keywords: daily group; twice daily; treatment; ruxolitinib cream ... See more keywords